Staurosporine Aglycon

Staurosporine Aglycon

SCHEMBL8124103

O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 13/20 1.00
CCND1 P24385 13/20 1.00
CCNE2 O96020 8/20 1.00
CCNE1 P24864 8/20 1.00
CDK2 P24941 8/20 1.00
CAMK2B Q13554 7/20 1.00
CAMK2G Q13555 7/20 1.00
CAMK2D Q13557 7/20 1.00
CAMK2A Q9UQM7 7/20 1.00
CCNB2 O95067 5/20 1.00
CDK1 P06493 5/20 1.00
CCNB1 P14635 5/20 1.00
CCNB3 Q8WWL7 5/20 1.00
CDK5 Q00535 3/20 1.00
CDK5R1 Q15078 3/20 1.00
PRKACA P17612 2/20 1.00
CCNA2 P20248 2/20 1.00
PRKACG P22612 2/20 1.00
PRKACB P22694 2/20 1.00
PRKCG P05129 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Staurosporine Aglycon SCHEMBL29406635 1.00 CDK4 (1.00) CDK4CCND1CCNE2CCNE1CDK2
Staurosporine Aglycon SCHEMBL30530825 1.00 CDK4 (1.00) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL14708731 0.89 CDK4 (0.80) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL8127691 0.87 CDK4 (1.00) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL1395043 0.86 CDK4 (1.00) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL22566985 0.86 CDK4 (0.74) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL29511391 0.86 GLI1 (1.00) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL9262153 0.86 CDK4 (1.00) CDK4CCND1CCNE2CCNE1CDK2
Granulatimide SCHEMBL4238896 0.84 CDK4 (1.00) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL14980870 0.83 PARP1 (1.00) CDK4CCND1CCNE2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0630242-B1 FURTHER INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY WELLCOME FOUND (GB) 1999-01-20 EP claimed
EP-0630242-A1 FURTHER INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY THE WELLCOME FOUNDATION LIMITED (GB) 1994-12-28 EP claimed
WO-1993018766-A1 FURTHER INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY THE WELLCOME FOUNDATION LIMITED (GB) 1993-09-30 WO claimed
US-20230094365-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF SNAP BIO, INC. 2023-03-30 US disclosed
US-11319320-B2 PIM kinase inhibitor compositions, methods, and uses thereof SNAP BIO, INC. (US) 2022-05-03 US disclosed
US-11319320-B2 PIM kinase inhibitor compositions, methods, and uses thereof SNAP BIO, INC. (US) 2022-05-03 US disclosed
US-20200331914-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF SNAP BIO, INC. 2020-10-22 US disclosed
US-20200331914-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF SNAP BIO, INC. 2020-10-22 US disclosed
EP-3706735-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF Snap Bio, Inc. (US) 2020-09-16 EP disclosed
EP-3184537-B1 GLYCOSYLATED INDOLOCARBAZOLES, METHOD FOR OBTAINING SAME AND USES THEREOF UNIV OVIEDO (ES) 2020-07-08 EP disclosed
US-10166241-B2 Combination Therapy III TURUN YLIOPISTO (FI) 2019-01-01 US disclosed
EP-0642513-A1 INDOLOCARBAZOLE IMIDES AND THEIR USE GÖDECKE AKTIENGESELLSCHAFT (DE) 1995-03-15 EP disclosed
EP-0328000-B1 Indolocarbazole derivatives, process for their preparation and medicines containing same GOEDECKE AG (DE) 1995-01-18 EP disclosed
EP-0630242-A1 FURTHER INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY THE WELLCOME FOUNDATION LIMITED (GB) 1994-12-28 EP disclosed
WO-1993024491-A1 INDOLOCARBAZOLE IMIDES AND THEIR USE Gödecke Aktiengesellschaft (DE) 1993-12-09 WO disclosed
WO-1993018766-A1 FURTHER INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY THE WELLCOME FOUNDATION LIMITED (GB) 1993-09-30 WO disclosed
EP-0528030-A1 ANTITUMOR BE-13793C DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-02-24 EP disclosed
EP-0528030-A1 ANTITUMOR BE-13793C DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-02-24 EP disclosed
WO-1991018003-A1 ANTITUMOR BE-13793C DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 1991-11-28 WO disclosed
EP-0328000-A2 Indolocarbazole derivatives, process for their preparation and medicines containing same GÖDECKE AKTIENGESELLSCHAFT (DE) 1989-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230094365-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF PIM1, PIM3, PIM2 CDK4 198/4885CCND1 2406/4885CCNE2 3529/4885
US-20200331914-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF PIM1, PIM2, PIM3 CDK4 221/4885CCND1 1985/4885CCNE2 2281/4885
US-10166241-B2 Combination Therapy III HDAC4, HDAC3, HDAC5 CDK4 68/4885CCND1 1174/4885CCNE2 1781/4885
US-11319320-B2 PIM kinase inhibitor compositions, methods, and uses thereof PIM1, PIM2, PIM3 CDK4 221/4885CCND1 1985/4885CCNE2 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.